Author Archives: Marta Figueiredo

Cosentyx Safe, Effective Through 5 Years of Treatment, Novartis Announces

Five-year treatment with Cosentyx (secukinumab) is safe and effective in easing signs and symptoms of ankylosing spondylitis (AS), according to results of a Phase 3 extension clinical trial. This new data are scheduled to be presented Oct. 23 at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual…

UCB’s Bimekizumab Shows Promising Results in AS Clinical Trial

UCB biopharma’s experimental therapy bimekizumab (CDP-4940, UCB-4940) significantly improved ankylosing spondylitis (AS) symptoms after 12 weeks of treatment in the Phase 2b BE AGILE trial (NCT02963506). Although no cure has been discovered yet for AS, disease symptoms can be lessened with drugs that decrease pain and inflammation.